Experience in Intra-arterial Chemotherapy using Two Protocols for the Treatment of OSCC over Two Decades at the University Hospital Vienna

• Published in: Clinics (São Paulo, Brazil) Brazil), 2018-01, Vol.73, p.e433, Article e433
• Main Authors: Eder-Czembirek, Christina, Rechinger, Sascha, Kornek, Gabriela, Selzer, Edgar, Seemann, Rudolf
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols - administration & dosage; Bleomycin - administration & dosage; Carcinoma, Squamous Cell - drug therapy; Cisplatin; Cisplatin - administration & dosage; Female; Fluorouracil - administration & dosage; Head and Neck; Humans; Infusions, Intra-Arterial; Intra-Arterial Chemotherapy; Kaplan-Meier Estimate; Locally Recurrent; Male; MEDICINE, GENERAL & INTERNAL; Methotrexate; Methotrexate - administration & dosage; Middle Aged; Mouth Neoplasms - drug therapy; Neoplasm Recurrence, Local; Neoplasm Staging; Oral Squamous Cell Carcinoma; Original; Retrospective Studies; Treatment Outcome; Young Adult
• ISSN: 1807-5932; 1980-5322; 1980-5322
• DOI: 10.6061/clinics/2018/e433

This retrospective study performed a comprehensive analysis of the usage of intra-arterial chemotherapy (iaCh) for locally recurrent UICC stage IV oral squamous cell carcinoma (OSCC) over two decades at the Department of Cranio-Maxillofacial and Oral Surgery at the University Hospital Vienna to assess the utility of its future use. Between 1994 and 2014, iaCh was indicated in 48 OSCC cases. In these, the two most frequent iaCh schemes, cisplatin/5-fluorouracil (Cis/5-FU) and methotrexate/bleomycin (MTX/Bleo), were chosen for further analysis. The effect on survival of two distinct intra-arterial protocols and their covariates were analyzed with the Kaplan-Meier method as well as univariate and multivariate Cox proportional hazard regression models. The mean follow-up period was 29.91 months. The two intra-arterial chemotherapy groups did not differ significantly in sample size, demographic data or therapeutic covariates. The Cis/5-FU iaCh regimen was associated with significantly better overall survival (median OS 2.6 years vs. 1.3 years; p=0.002) and had a beneficial effect on survival (HR=3.62, p=0.015). Side effects occurred at a frequency similar to that described in the literature for intravenous chemotherapy (ivCh). These results suggest a preference for administering Cis/5-FU for iaCh. Nevertheless, due to economic considerations in healthcare expenditures, there is no future for iaCh in the treatment of head and neck carcinomas because ivCh is known to be equivalent.